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Human herpesvirus 6 (HHV-6) comprises two viral species, HHV-6A and
HHV-6B, closely related but differing for pathogenic and biological characteristics.
Both viral species are predominantly lymphotropic, infecting T lymphocytes and other
lymphoid cells, including natural killer (NK) cells. The interactions between HHV-6
and NK cells have been scarcely studied, but it has become clear that NK cells are not
only crucial in immune protection during the early phases of infection, but also that
HHV-6 infection can affect NK cell functions. In this report, we shortly summarize the
interactions between HHV-6 and NK cells.
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Human Herpesvirus 6A (HHV-6A) and HHV-6B Infection
HHV-6 was ﬁrst isolated in 1986 [1]. Soon it became evident that viral
isolates fall into two distinct groups, which, although very similar from a genetic
point of view, can be easily distinguished on the basis of biological, immuno-
logical, and cell tropism characteristics [2]. Originally, the two viral groups were
designated as HHV-6A and HHV-6B variants, but recently, it was recognized that
each variant has such speciﬁc characteristics to be classiﬁed as different viral
species [3]. HHV-6A and HHV-6B have collinear genomes, over 90% aminoacid
identity, and conserved epitopes cross-reactive to monoclonal antibodies. How-
ever, there are species-speciﬁc monoclonal antibodies; the two viruses have
different in vitro cell tropism and more importantly have different epidemiology
and pathogenic associations. HHV-6 research has often suffered from lack of
discrimination between HHV-6A and HHV-6B, and potentially conﬂicting or
negative results published in the scientiﬁc literature may be ascribed to the
biological and pathogenic differences between the two species.
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HHV-6B primary infection occurs in the early childhood (between 6 months
and 2 years of age) and is associated with exanthem subitum (2–3 days of fever
followed by rash) and other benign febrile diseases, whereas HHV-6A primary
infection has still to be precisely characterized: it is thought to occur later in life
and is possibly asymptomatic, potentially due to the fact that existing HHV-6B
protective immunity exerts its effects also on HHV-6A [4]. HHV-6 (mostly -6B) is
frequently detected in saliva and salivary glands [5] and therefore it is possible that
the main route of transmission is represented by the salivary route. Other routes of
transmission (i.e., blood transplantation and breast feeding) have occasionally
been reported. In addition, HHV-6, mainly HHV-6A, might be transmitted by the
sexual route [6, 7].
HHV-6A and -6B have a preferential tropism for lymphoid cells (T cells,
monocytes/macrophages) but in vitro and in vivo, they can also infect other cell
types (endothelial cells, ﬁbroblasts, NK cells, glial cells, astrocytes, hepatocytes,
etc.) [8], with different cell target and/or efﬁciency of infection for the two viral
species. In fact, the two viruses use different cell receptors to recognize and attach
to the cell membrane. HHV-6A uses CD46, a molecule expressed on the surface of
all human cells [9], whereas HHV-6B uses CD134/OX40 [10], present only on
speciﬁc cell types.
Infection with HHV-6B, and less frequently HHV-6A, is widespread in the
human adult population and seropositivity rates are over 90%. However, since
serological assays do not allow to discriminate between HHV-6B and HHV-6A, it
is not possible to determine the effective seroprevalence of each virus in the human
population.
Like all herpesviruses, HHV-6 establishes latent lifelong persistent infec-
tions in the host, most frequently in lymphoid cells but also in the brain and bone
marrow, as proven by the PCR detection of viral DNA in peripheral blood
lymphocytes or different tissues from healthy adults. Interestingly, most of these
HHV-6 positive cases contain HHV-6B DNA, while HHV-6A is very infrequently
detected.
During latency, HHV-6 does not replicate and expresses only few genes;
therefore, the absence of transcription from lytic genes in the presence of latency-
associated mRNAs (i.e., U94) is indicative of true latency [11]. Reactivations occur
frequently, particularly in immunocompromised patients. HHV-6 reactivation in
transplant recipients can be associated with several different clinical conditions,
including encephalitis, graft failure and graft-versus-host disease, pneumonia,
cognitive dysfunction, thrombotic microangiopathy, and human cytomegalovirus
reactivation. Reactivation is also supposed to play a role in drug reaction with
eosinophilia and systemic symptoms, a serious adverse drug reaction [12].
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Both variants of HHV-6 have been suggested as a possible trigger
for multiple sclerosis, several direct and indirect evidences support this hypothesis,
but conclusive evidence is still missing [13]. Other pathological conditions that
have been associated with HHV-6 include Hashimoto’s autoimmune thyroiditis
(HHV-6A) [14, 15], myocarditis and chronic cardiomyopathy (both species),
mesial temporal lobe epilepsy (HHV-6B) [16], and mononucleosis [17].
An interesting feature of HHV-6 is that approximately 1% of the
human population carry the complete chromosomally integrated HHV-6 DNA
(ciHHV-6) in their genome in all the host cells, both somatic and germinal,
and transmit it vertically to the offspring as a Mendelian character [18]. Both
HHV-6 species can integrate, ciHHV-6 can reactivate, and its pathogenic
relevance is still to be determined. However, in such cases, high HHV-6
DNA loads normally associated with ciHHV-6 could be misinterpreted as an
active infection.
Natural Killer Cells
Natural killer (NK) cells derive from the lymphoid lineage and constitute an
innate immune mechanism important in the control of viral infections [19]. Their
protective role has been shown against a large number of viral species, including
human immunodeﬁciency virus, papillomaviruses, ﬂaviviruses, paramyxoviruses,
and herpesviruses. They have direct and indirect protective effects against viral
infections. Direct antiviral effect is represented by cytolytic killing of virus-
infected target cells. Indirect effects include early production of proinﬂammatory
cytokines, including interferon gamma. Increasing evidence shows that the NK
cells have an important regulatory effect on stimulation of adaptive immunity [20].
NK cell cytotoxic activity is controlled by several activating and inhibitory
receptors present on the NK cell membrane, belonging to different functional
and genetic groups. The complex balance stemming from the engagement of
activating and inhibitory receptors determines whether NK cells are activated or
not. In general, inhibitory receptors bind self-molecules, such as major histocom-
patibility complex-1 (MHC-1) [21]. When target cells express MHC-1 molecules,
inhibitory receptors are engaged and NK cells are normally non-activated. Often,
virus infection alters the expression of MHC-1 molecules. In addition, activating
NK cell receptors can bind non-self peptides and stress-induced molecules.
Therefore, during viral infection, there is a lower inhibition of NK cells, due to
the altered levels of MHC-1, and a signiﬁcant activation of their functions, due to
the engagements of activating receptors.
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HHV-6 Infection and NK Cells
HHV-6 has the ability to infect NK cells [22]. Perhaps, it is even more relevant
for the observation that HHV-6 infection of target non-NK cells has signiﬁcant
effects on NK cell functions. In fact, NK cells are cytotoxic for HHV-6-infected
autologous cells, and NK activity on HHV-6 is affected by still undetermined
polymorphic elements on the target cell that restricts NK cell recognition [23].
HHV-6 infection of peripheral blood mononuclear cells results in the upregulation
of NK cell cytotoxicity during the ﬁrst 48 h of infection, and this effect was mediated
by secretion of IL-15 [24].
NK cell activity signiﬁcantly increases during the acute phase of primary
infection, in conjunction with the rash appearance, and decreases in the conva-
lescent phase, suggesting that NK cell activity plays a central role in recovery [25].
Kumagai et al. [26] showed that NK cells play a major role in resolving acute phase
infection, while speciﬁc lymphocyte activity develops later. Interestingly, veterans
affected by Gulf War syndrome had high antibody levels to HHV-6 (as well as to
all other HHVs) concomitant with a signiﬁcant lower activity of NK cells [27],
indirectly conﬁrming the important role of NK cells in controlling HHV-6 (and
other HHV) infection. Interestingly, patients with Hashimoto’s thyroiditis, a
condition associated with HHV-6A, show increased levels of a speciﬁc subset of
NK cells (CD56bright), as well as cytotoxic activity speciﬁc for HHV-6 [15],
suggesting that these patients might have an altered response to HHV-6. Analysis
of endometrial tissue from idiopathic infertile women tissue positive of HHV-6A
shows a reduction of CD56bright-resident endometrial NK cells as well as
increased activation and cytotoxicity toward HHV-6-infected cells [7].
Conclusions
Taken together, these observations show the importance of NK cells in
controlling HHV-6 infection, and that HHV-6 can modify the function of NK
cells. In particular, HHV-6 infection is also able to modify NK cell miRNAs and
transcription factors expression [28], suggesting an impact on the effector func-
tions of NK cells.
Results previously published by our group with different herpesvirus, herpes
simplex type 1 and HHV-8, show that the expression of a speciﬁc inhibitory NK
cell receptor (KIR2DL2) might be associated with the inability of NK cells to
control infection [29–33]. We are currently testing the hypothesis that expression
of the inhibitory KIR2DL2 receptor is indeed associated with increased suscepti-
bility to HHV-6 infection.
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